Clinical trials: Influenza Vaccines
Healthy
A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus
This is a Phase I, parallel design open label study to evaluate safety, tolerability and immunogenicity of nine different formulation of two individual H1 and one H5 HA plasmid administered intradermally followed by…
- Trial name
- NCT01405885
- Testing
- INO-3605, INO-3609, INO-3401
- Where
- 3 sites in United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Influenza, Human
Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)
The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza…
- Trial name
- NCT01390792
- Testing
- Zanamivir hydrate
- Volunteers
- 622 people
- Sponsor
- GlaxoSmithKline
Influenza A
Study of VIR-2482 in Healthy Volunteers
This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness.
- Trial name
- NCT04033406
- Testing
- VIR-2482
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vir Biotechnology, Inc.
Influenza
Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains
The study is to assess whether the influenza vaccine Inflexal V for season 2012/2013 fulfills the EMA requirements for re-registration of influenza vaccines.
- Trial name
- NCT01631110
- Testing
- Inflexal V
- Where
- Switzerland
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza, Healthy
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season
This prospective annual release study is designed to evaluate the safety of 3 new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2015-2016 influenza season
- Trial name
- FluMist (NCT02473510)
- Testing
- Trivalent Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
GCP
Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.
To evaluate the inter-batch consistency (CI) of quadrivalent influenza vaccine (split virion) among healthy people aged 18-59 years； Secondly, to evaluate the safety and immunogenicity of quadrivalent influenza vaccine (split…
- Trial name
- NCT06334510
- Testing
- One dose of quadrivalent influenza virus split vaccine was administered
- Where
- China
- Volunteers
- 4,900 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Bacterin Co. Ltd.
Influenza,Human, COVID-19
A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People
This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed.
- Trial name
- NCT06683352
- Testing
- Investigational Influenza Vaccine, COVID-19 Vaccine, Investigational Influenza/COVID-19 Vaccine
- Where
- 22 sites in United States
- Volunteers
- 1,353 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Influenza
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination
Immunogenicity and safety of a cell-derived influenza vaccine in adults aged >= 18 and <= 64 years, plus revaccination
- Trial name
- NCT00889889
- Testing
- Cell-Derived Trivalent Subunit Influenza Vaccine
- Where
- 15 sites in United States
- Volunteers
- 1,270 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Influenza
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years
This phase I/II, randomized, modified double-blind, multi-center study assessed the safety and immunogenicity of a high-dose Quadrivalent influenza vaccine (QIV-HD) in older adults (greater than or equal to [>=] 65 years).
- Trial name
- NCT03233217
- Testing
- QIV-HD by IM, QIV-SD by SC, QIV-HD by SC
- Where
- 2 sites in Japan
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pandemic Influenza Prevention
A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
The purpose of this study is to evaluate the immunogenicity and safety of two intramuscular vaccinations with BLB-750 in healthy Japanese adults.
- Trial name
- NCT03370289
- Testing
- BLB-750 Vaccine (Qinghai RG strain)
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza
Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza
To demonstrate that the efficacy over a defined surveillance period against culture-confirmed influenza-illness caused by community-acquired subtypes antigenically similar to those contained in the vaccine, in adults aged at…
- Trial name
- FluMist (NCT00192413)
- Testing
- Cold-adapted influenza vaccine trivalent (CAIV-T), Trivalent Inactivated Vaccine (TIV)
- Where
- 4 sites in South Africa
- Volunteers
- 3,009 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Characterisation of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model
The study will characterise Influenza A/Perth/16/2009(H3N2) virus in healthy participants using the viral challenge model. The study includes two cohorts.
- Trial name
- NCT02525055
- Testing
- Infectious titre 1 (H3N2), Infectious titre 2 (H3N2), Infectious titre 3 (H3N2)
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Hvivo
Influenza
Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
The objectives of this Phase I/II study are to assess the safety and immunogenicity of two different dose levels of a non-adjuvanted H5N1 influenza vaccine in a healthy young adult population.
- Trial name
- NCT00517517
- Testing
- Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Healthy
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)
A phase I/II, randomized, single-blind, placebo-controlled escalating double-dose safety study of an intramuscular universal influenza vaccine (Multimeric-001) injected to healthy volunteers.
- Trial name
- NCT00877448
- Testing
- Adjuvanted Multimeric-001 250 Mcg, Multimeric-001 250 Mcg, Phosphate Buffered saline
- Where
- Israel
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Novel 2009 Influenza H1N1, Influenza, Human
Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents
This is a single-blind, reference drug controlled study to assess safety and tolerability of FLUVAL P H1N1 monovalent influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing 6 mcgHA per 0.5mL…
- Trial name
- NCT01407978
- Testing
- Vaccination with Fluval P monovalent influenza vaccine, Vaccination with Fluval AB, Vaccination with Fluval AB Novo
- Where
- Hungary
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Human Influenza
A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.
The present study is designed to evaluate the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years.
- Trial name
- NCT02427750
- Testing
- Aggripal®
- Where
- Brazil
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
The present study aims to evaluate safety and immunogenicity of one dose of a commercially available Surface Antigen, Inactivated Influenza Vaccine, Formulation 2006-2007, in non-elderly adult and elderly subjects.
- Trial name
- NCT00342940
- Testing
- influenza surface antigen inactivated vaccine
- Where
- United Kingdom
- Sponsor
- Novartis
Influenza, Flu
Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine
This phase I-like, open-label, monocenter, descriptive, single-arm clinical safety study will investigate the Shenzhen quadrivalent influenza vaccine (Shz QIV) in 100 participants aged 6 months and older in China.
- Trial name
- NCT03430089
- Testing
- Shz QIV 0.25 mL, 2 doses, Shz QIV 0.5 mL, 2 doses, Shz QIV 0.5 mL, single dose
- Where
- China
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00971425
- Testing
- Pandemrix (GSK investigational influenza GSK2340272A vaccine), Fluarix™
- Where
- 6 sites in Germany
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to determine the immunogenicity and tolerability of one 0.5 mL intramuscular (IM) injection of FLUVAL AB-like trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01459276
- Testing
- Vaccination with FAB-6011, Vaccination with FluvalAB
- Where
- 7 sites in Hungary
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.